These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases. Smaill JB; Lee HH; Palmer BD; Thompson AM; Squire CJ; Baker EN; Booth RJ; Kraker A; Hook K; Denny WA Bioorg Med Chem Lett; 2008 Feb; 18(3):929-33. PubMed ID: 18191399 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of 5-substituted 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as check point 1 kinase inhibitors. Sako Y; Ichikawa S; Osada A; Matsuda A Bioorg Med Chem; 2010 Nov; 18(22):7878-89. PubMed ID: 20943405 [TBL] [Abstract][Full Text] [Related]
11. Design of granulatimide and isogranulatimide analogues as potential Chk1 inhibitors: Study of amino-platforms for their synthesis. Lavrard H; Rodriguez F; Delfourne E Bioorg Med Chem; 2014 Sep; 22(17):4961-7. PubMed ID: 25047935 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3-diones, and 2-aminopyridazino[3,4-a]pyrrolo[3,4-c]carbazole-1,3,4,7-tetraone. Conchon E; Anizon F; Aboab B; Golsteyn RM; Léonce S; Pfeiffer B; Prudhomme M Eur J Med Chem; 2008 Feb; 43(2):282-92. PubMed ID: 17502122 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of new dipyrrolo[3,4-a:3,4-c]carbazole-1,3,4,6-tetraones, substituted with various saturated and unsaturated side chains via palladium catalyzed cross-coupling reactions. Hénon H; Anizon F; Golsteyn RM; Léonce S; Hofmann R; Pfeiffer B; Prudhomme M Bioorg Med Chem; 2006 Jun; 14(11):3825-34. PubMed ID: 16460946 [TBL] [Abstract][Full Text] [Related]
15. New N-1,N-10-bridged pyrrolo[2,3-a]carbazole-3-carbaldehydes: synthesis and biological activities. Giraud F; Bourhis M; Nauton L; Théry V; Herfindal L; Døskeland SO; Anizon F; Moreau P Bioorg Chem; 2014 Dec; 57():108-115. PubMed ID: 25305721 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors. Saleem RS; Lansdell TA; Tepe JJ Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028 [TBL] [Abstract][Full Text] [Related]
17. A three-step synthesis from rebeccamycin of an efficient checkpoint kinase 1 inhibitor. Anizon F; Golsteyn RM; Léonce S; Pfeiffer B; Prudhomme M Eur J Med Chem; 2009 May; 44(5):2234-8. PubMed ID: 18602198 [TBL] [Abstract][Full Text] [Related]
18. Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. Gazzard L; Williams K; Chen H; Axford L; Blackwood E; Burton B; Chapman K; Crackett P; Drobnick J; Ellwood C; Epler J; Flagella M; Gancia E; Gill M; Goodacre S; Halladay J; Hewitt J; Hunt H; Kintz S; Lyssikatos J; Macleod C; Major S; Médard G; Narukulla R; Ramiscal J; Schmidt S; Seward E; Wiesmann C; Wu P; Yee S; Yen I; Malek S J Med Chem; 2015 Jun; 58(12):5053-74. PubMed ID: 25988399 [TBL] [Abstract][Full Text] [Related]
19. Synthesis of Cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA damage kinase, checkpoint kinase 1. Perron-Sierra FM; Kucharkzyk N; Boucley C; Guyard-Daumas C; Sciberras S; Fouache C; Plantier S; Studeny A; Bossard C; Casara PJ; Golsteyn RM Anticancer Agents Med Chem; 2012 Mar; 12(3):194-201. PubMed ID: 22044003 [TBL] [Abstract][Full Text] [Related]
20. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors. Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]